In vitro drug combination of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil with anti-human immunodeficiency virus or anticancer nucleosides.
H Machida, N Ashida, T Ikeda, S Sakata, M Baba, S Shigeta
Index: Antimicrob. Agents Chemother. 36(1) , 214-6, (1992)
Full Text: HTML
Abstract
1-beta-D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and E-5-(2-bromovinyl)uracil, a metabolite of BV-araU, did not affect either the anti-human immunodeficiency virus activity or the cytotoxicity of azidothymidine in MT-4 and MOLT-4 cells. Similarly, the bromovinyl compounds did not affect the in vitro antitumor activities of arabinosylcytosine, 5-fluorouracil, and 5-fluoro-2'-deoxyuridine. The anti-varicella-zoster virus activity of BV-araU was not influenced by azidothymidine, 2',3'-didehydro-2',3'-dideoxythymidine, or arabinosylcytosine, whereas relatively high concentrations of fluorinated antitumor agents enhanced the anti-varicella-zoster virus activity.
Related Compounds
Related Articles:
1999-11-01
[Magn. Reson. Med. 42(5) , 936-43, (1999)]
1986-05-15
[Biochem. Pharmacol. 35(10) , 1647-53, (1986)]
1986-02-01
[J. Med. Chem. 29 , 213, (1986)]
2000-05-01
[Mol. Pharmacol. 57(5) , 899-905, (2000)]
1995-02-17
[J. Chromatogr. B, Biomed. Appl. 664(2) , 357-63, (1995)]